石藥集團(01093.HK):“甲磺酸侖伐替尼膠囊”獲藥品註冊批件
格隆匯1月12日丨石藥集團(01093.HK)發佈公吿,集團附屬公司石藥集團歐意藥業有限公司開發的“甲磺酸侖伐替尼膠囊(4mg)”已獲得中國國家藥品監督管理局頒發藥品註冊批件,並視同通過仿製藥質量和療效一致性評價。
根據披露,侖伐替尼是一種酪氨酸激酶受體(RTK)抑制劑,可抑制血管內皮生長因子(VEGF)受體VEGFR1(FLT1)、VEGFR2(KDR)和VEGFR3(FLT4)的激酶活性,另外還可抑制其它促血管生成和腫瘤發生通路相關的RTKs,包括成纖維細胞生長因子受體(FGFR)等。甲磺酸侖伐替尼膠囊適用於既往未接受過全身系統治療的不可切除的肝細胞癌患者,其在中國、日本和美國等國家均已被納為治療中晚期肝癌的一線藥物。該產品的獲批將進一步豐富集團的產品組合,並有助於集團在抗腫瘤領域的發展。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.